CIRSE 2023 - 9-13 September 2023

Miami and Montpellier,March 26, 2026 - Medical robotics company Quantum Surgical has obtained market authorization from the Taiwan Ministry of Health and Welfare (TMHW) for the use and commercialization of its Epione® robotic platform in Taiwan. Epione enables early and minimally invasive treatment of tumors. Nearly 140,000 new cancer case sare diagnosed in Taiwan each year[1].

Quantum Surgical is a company specializing in robotics and AI and develops theearly-stage tumor-treating Epione^® robotic platform. Epione assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor.

Epione allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.

Epione can be used to treat abdominal (including the liver, kidneys, and pancreas), chest and musculoskeletal structures tumors and lesions. Over1,400 patients have already been treated in Europe and the United States.

The TMHW market authorization allows for offering this innovative, better targeted, andminimally invasive treatment to new patients in Taiwan.

"Thanks to the Taiwan Ministry of Health and Welfare market authorization, we are very excited to be able to offer our Epione solution to interventional oncologists in Taiwan. This is an important step that will provide Taiwanese patients with an innovative and minimally invasive treatment to treat their tumors at an early stage, while improving their comfort" says Bertin Nahum, President and Co-founder of Quantum Surgical.

"The Taiwan Ministry of Health and Welfare market authorization confirms the effectiveness of Epione and, above all, the relevance of its deployment in the territory,where nearly 140,000 new cases of cancer are diagnosed each year" explains Laetitia Messner, VP of Clinical Development of Quantum Surgical.

The Epione device is CE marked for abdomen, chest and musculoskeletal structures indications, and FDA cleared for abdominal ablation indication.

[1] HPA, 2023

‍

Miami, Florida, and Montpellier, France, February 24, 2026 – Quantum Surgical, a company specializing in minimally invasive robotic-assisted cancer treatment, today announced the acquisition of NeuWave Medical, Inc., a medical device company whose products are used by physicians in over 70% of the top cancer centers in the United States. This acquisition supports Quantum Surgical’s strategy to democratize robotic-assisted tumor ablation treatments to reduce cancer mortality.

Quantum Surgical and NeuWave Medical, Inc. – both of which share an extensive focus on innovation to improve cancer patients’ outcomes – will operate as subsidiaries of Precision IO Group Inc., the newly created parent company led by medtech veteran Kurt Azarbarzin, who was recently appointed CEO.

The group’s ambition is to become a leader in the interventional radiology industry, with a strong focus on precision and remote procedures.

Quantum Surgical specializes in robotics and AI and has developed the Epione® robotic platform for treating early-stage tumors. Epione assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to treat the tumor.

“At Quantum Surgical, we are committed to democratizing procedural know-how through robotics, and expanding high-quality cancer care for patients. Acquiring NeuWave Medical, Inc. is a natural and strategic step in that mission” said Bertin Nahum, President and co-founder of Quantum Surgical. “Innovation is our north star and we are thrilled to join forces with a passionate team of experts to drive innovation even further and shape the future of interventional oncology.”

NeuWave offers market-leading, clinically proven microwave ablation technology that provides a physician-friendly workflow during percutaneous ablations and is used in 70% of the top cancer centers in the USA.

“We’re proud to join the Quantum Surgical team and continue supporting physicians in their mission to treat cancer patients,” said Leah Kissling, President of NeuWave Medical, Inc. “We look forward to combining our capabilities with Quantum Surgical to drive innovation and help transform the future of cancer care.”

Innovation at the Core: Expanding Cancer Care Through Remote Procedures

The two companies rely on purpose-driven, highly experienced teams committed to transforming cancer treatment through consistent, globally recognized innovation. Bringing the two entities together was a natural step toward creating a new innovation dynamic and an expanded market presence.

Precision IO Group Inc. is already working to break down geographical barriers by enabling remote interventions. The new remote interventions project aims to expand access to robotic-assisted percutaneous procedures by leveraging world-renowned experts for remote trajectory planning and results assessment, using Epione tools.

Enabling remote interventions benefits all stakeholders: more patients can access top-tier physicians and minimally invasive care without traveling long distances. Physicians will be able to extend their expertise with greater geographic reach, collaborate in real time with specialists worldwide, and perform highly precise procedures with enhanced visualization and control.

Medtech Leader Joins as New Group CEO

Seasoned Medtech leader Kurt Azarbarzin has been appointed to lead the new entity, Precision IO Group Inc. He is the former Founder and CEO of SurgiQuest, Inc., a medical device company focused on advancing minimally invasive surgery, and also served as CEO of EndoQuest Robotics and Verb Surgical, a robotic joint venture between Johnson & Johnson and Google. Most recently, Mr. Azarbarzin became a Partner at Frazier Healthcare Partners, where he advises and supports high-growth healthcare companies at critical stages of development and commercialization.

“I am excited and honored to join Precision IO Group Inc. as CEO,” said Kurt Azarbarzin. “Quantum Surgical and NeuWave Medical, Inc. are highly complementary and share an incredible vision for the future. I have met both teams and am impressed by the pride and passion they bring to their work to improve patient care. I believe that their technologies, both independently and combined, have the potential to position us as leaders of the industry, and to transform cancer care on a global scale. Drawing on my 40 years of experience in minimally invasive surgery, I am convinced that AI, robotics and enabling remote interventions are game-changers for cancer care and interventional radiology.”

“Quantum Surgical is expanding fast and will grow even faster with the acquisition of NeuWave Medical, Inc.. We are excited to count on Kurt’s experience and leadership to take us to the next phase for our company,” says Bertin Nahum, President and co-founder of Quantum Surgical.

Guaranteed Business Continuity

While their activities complement each other and robust, cross-organizational enhancements are being developed, both companies will continue to operate independently to ensure a smooth and uninterrupted experience for their users:

- The Epione robotic solution remains an open-architecture platform compatible with common CT imaging and tumor ablation modalities, allowing physicians the flexibility to treat distinct tumor morphologies.

- The market-leading, clinically proven microwave ablation technology developed by NeuWave Medical, Inc. is minimally invasive and can be used independently or combined with other therapies to improve patient outcomes and will remain available to physicians and patients.

Physicians’ workflow and practice, therefore, remain unchanged.

The Epione device is CE marked for abdominal, chest, and musculoskeletal structures indications, and FDA cleared for the abdominal ablation indication. To date, more than 1,400 patients have already been treated in Europe and the United States.

The acquisition and combined growth is fueled by Investment from Ally Bridge Group, the largest investor in Precision IO Group. In connection with the transaction, Stifel acted as exclusive financial advisor to Quantum Surgical. McDermott Will & Schulte LLP served as Quantum Surgical’s legal advisor.

‍

The European Conference on Interventional Oncology 2026 will be held in Basel, Switzerland, from April 26 to 30, 2026.

Organized by the CIRSE, this yearly event brings together interventional radiologists, medical oncologists, surgeons, and numerous other healthcare professionals around the latest advancements in Interventional Oncology. The European Conference on Interventional Oncology continues to serve as the global home for those pioneering the future of minimally invasive cancer care.

‍

Don’t miss the opportunity to learn more about Epione^®at ECIO:

• Satellite Symposium - More information to come!
  
  • Monday, April 27 - 14:00
  • Auditorium 2

• Hands-on Workshop - HDT-TA 25.1 Tumour ablation: confirmation software
  
  • Monday, April 27 - 17:00-18:30 - More information to come!
  • Tuesday, April 28 - 8:30-10:00 - More information to come!

‍

‍

EVENT DETAILS

• Date: April 26-30, 2026
• Venue: Congress Center Basel - Basel, Switzerland